A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia.

Autor: Advani AS; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH. Electronic address: advania@ccf.org., Tse W; Department of Hematology/ Oncology, Metro Health, Cleveland, OH., Li H; Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH., Jia X; Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH., Elson P; Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH., Cooper B; Department of Hematology/ Oncology, University Hospitals of Cleveland, Cleveland, OH., Ali-Osman F; Department of Hematology/ Oncology, Duke University, Durham, NC., Park J; James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY., Rao AV; Duke Cancer Institute, Duke University, Durham, NC; Current affiliation: PACT Pharma, South San Francisco, CA., Rizzieri DA; Duke Cancer Institute, Duke University, Durham, NC., Wang ES; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY., Cotta CV; Department of Pathology, Cleveland Clinic, Cleveland, OH., Kalaycio M; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH., Sobecks RM; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH., Rouphail B; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH., Maciejewski JP; Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Fensterl J; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH., Carew JS; University of Arizona Cancer Center, Leon Levy Cancer Center, Tuscon, AZ., Foster B; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH., Rush ML; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH., Tripp B; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH., Adams D; Department of Hematology/ Oncology, Duke University, Durham, NC., Corrigan D; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH., Griffiths EA; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY., Sekeres MA; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH.
Jazyk: angličtina
Zdroj: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2021 Feb; Vol. 21 (2), pp. 113-118. Date of Electronic Publication: 2020 Dec 03.
DOI: 10.1016/j.clml.2020.11.018
Abstrakt: Introduction: Adults with acute myeloid leukemia (AML) have a high rate of remission; however, more than 50% relapse. C-kit is expressed in approximately 60% of patients with de novo AML and represents a potential therapeutic target.
Materials and Methods: Patients with newly diagnosed AML received 12 months of imatinib mesylate as maintenance therapy after the completion of post-remission therapy. The primary objective was to determine whether this approach improved progression-free survival (defined as no relapse and no death) compared with historical controls.
Results: The median progression-free survival of patients < 60 years of age was 52.1 months (historical control, 13 months) and for patients ≥ 60 years of age was 10.7 months (historical control, 8 months). The median level of AF1q expression was high (9.59), and 84% of patients had moderate or high levels of drug-resistance factors.
Conclusions: Imatinib maintenance therapy may improve the outcome of newly diagnosed patients with AML who are < 60 years of age.
(Copyright © 2020 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: